NEW HAVEN, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Peter Milligan as its new Chief Financial Officer, effective immediately. He will succeed current CFO Paul Estrem, who is retiring from Melinta on October 1, 2018.
Milligan is an accomplished executive and established corporate leader who brings nearly 30 years of financial leadership experience, with extensive experience in managing all aspects of corporate and operational financial matters, including numerous capital market transactions.
“We are excited to have Peter join our leadership team at this important moment for Melinta,” said Dan Wechsler, President and CEO of Melinta. “His nearly three decades of financial leadership experience across all aspects of corporate and operational finance will be a strong asset to our company as we continue to grow and build upon our position as the world’s leading dedicated antibiotics company.”
“I would like to thank Paul for his exceptional leadership during the last five years with Melinta, helping to deliver the company to the strong position it stands in today. He has been instrumental in achieving numerous milestones, including the reverse merger with Cempra, the acquisition of the Infectious Disease business from The Medicines Company and the recent launch of Baxdela™ (delafloxacin). He leaves the company well-positioned for future success.”
Milligan most recently served as the Chief Financial Officer of G&W Laboratories, a privately held generic pharmaceutical company where he had oversight and leadership of all financial aspects of the company, including financial planning and analysis, accounting, internal control, treasury, and tax. Prior to that he was Senior Vice President and CFO of Exelis, Inc. (NYSE: XLS), a leading global defense and aerospace company effective with its 2011 spin-off from ITT through the sale of the business to Harris Corp in 2015. Prior to that he held various senior finance roles within ITT, Inc. He also spent over 10 years at AT&T in roles of increasing responsibility within their finance function.
Milligan holds a M.B.A. from New York University with a concentration in Finance and Economics and a B.B.A. in Accounting from Hofstra University.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.comfor more information.
